MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Molecular Cancer Therapeutics
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

759 results · 1 filter active ·
Results by year
20042025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
759 works in the cohort · of 4,299,418page 8 of 16

Labels cover 2 of 759 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 759 of 759 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
Johanna C. Bendell, Susanna V. Ulahannan, Quincy S. Chu, Manish R. Patel, Ben George, Renee Landsberg +7 more
2019· article· en· Molecular Cancer Therapeutics· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
2
citations
affunlabeled
Abstract B49: GRN1005 phase I studies: Final results.
Patrick Y. Wen, Jan Drappatz, Andrew Brenner, Tom Mikkelsen, David Schiff, Steven S. Rosenfeld +9 more
2011· article· en· Molecular Cancer Therapeutics· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
2
citations
affunlabeled
Abstract B169: Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring <i>CCNE1</i> amplification and/or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>
Elia Aguado-Fraile, Sunantha Sethuraman, Adam Petrone, Emeline Bacqué, Alison M. Schram, Stéphanie Lheureux +5 more
2023· article· en· Molecular Cancer Therapeutics· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
2
citations
affunlabeled
Advancing Preclinical Biology for Ewing Sarcoma: An International Effort
Filemon S. Dela Cruz, Elizabeth Stewart, Didier Surdez, Jessica D. Daley, Alice Soragni, Eleni M. Tomazou +23 more
2025· article· en· Molecular Cancer Therapeutics· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
2
citations
affunlabeled
Abstract C77: A novel BRCA2 targeting antisense oligonucleotide sensitizes human tumor cells to chemotherapy and radiotherapy - the induction of ‘complementary lethality’ by targeting DNA repair.
Mateusz Rytelewski, Jessica Tong, Adrian Buensucesco, Saman Maleki Vareki, Peter J. Ferguson, René Figueredo +4 more
2013· article· en· Molecular Cancer Therapeutics· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
1
citations
affunlabeled
Abstract A186: KIF14 is a novel therapeutic target for ovarian cancer.
Brigitte L. Thériault, Sanja Pajovic, Marcus Q. Bernardini, Patricia A. Shaw, Harvey Lim, Brenda L. Gallie
2011· article· en· Molecular Cancer Therapeutics· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
1
citations
← previousnext →

How this was built: Screen · Findings · About